Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
AssigneeInfections Disease Research Institute
InventorsYasuyuki Goto, Steven G. Reed
Life of this patent
Estimating the term…
Abstract
Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising multiple Leishmania antigens, in particular, KMP11, SMT, A2 and/or CBP, or immunogenic portions or variants thereof, as well as polynucleotides encoding such fusion polypeptides.
Claims11
An isolated fusion polynucleotide encoding a fusion polypeptide, wherein the fusion polypeptide comprises the amino acid sequence set forth as SEQ ID NO:
- 33, or or a sequence having at least 90% identity to SEQ ID NO:
- 33.
A composition comprising a polynucleotide in combination with at least one immunostimulant, wherein the polynucleotide encodes a fusion polypeptide comprising the amino acid sequence set forth as SEQ ID NO:33 or a sequence having at least 90% identity to SEQ ID NO:
- 33.
A method for inducing protective immunity against leishmaniasis in a mammal comprising administering to a mammal in need thereof a composition, wherein the composition comprises a polynucleotide in combination with at least one immunostimulant, wherein the polynucleotide encodes a fusion polypeptide comprising the amino acid sequence set forth as SEQ ID NO:33 or a sequence having at least 90% identity to SEQ ID NO:
- 33.
Dependencies are inferred from the claim text.